Carroll Investors’s Recursion Pharmaceuticals RXRX Stock Holding History

Carroll Investors's RXRX Position: Q2 2026 in Review

Carroll Investors reduced its Recursion Pharmaceuticals (RXRX) stake by 1.8% in Q2 2026, selling an estimated $30.2K and leaving 500,349 shares worth $1.84M. The position accounts for 0.78% of the portfolio, ranked #17.

Carroll Investors first reported a position in RXRX in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.95M in Q2 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

• Carroll Investors held 500,349 shares of Recursion Pharmaceuticals worth $1.84M as of Q2 2026.
• Carroll Investors sold 9,076 Recursion Pharmaceuticals shares in Q2 2026, an estimated $30.2K.
• Recursion Pharmaceuticals made up 0.78% of Carroll Investors's portfolio in Q2 2026, its #17 holding.
• Carroll Investors first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
• Carroll Investors's Recursion Pharmaceuticals position peaked at $1.95M in Q2 2025.
• 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Carroll Investors's 13F filing for Q2 2026, filed 3 Aug 2026.